文献速递临床试验与 GCP医学人工智能与信息学

MRI引导的纤维化消融与常规导管消融对持续性心房颤动患者房性心律失常复发的影响:DECAAF II随机临床试验

Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

DECAAF II多中心随机试验纳入843例持续性房颤患者,比较MRI引导的纤维化消融联合肺静脉隔离(PVI)与单纯PVI的疗效与安全性,主要终点为空白期后首次房性心律失常复发时间。结果显示两组复发率无显著差异(43.0% vs 46.1%,HR 0.95,95%CI 0.77-1.17,P=0.63),但纤维化消融组安全终点事件更多(2.2% vs 0,P=0.001)。

要点

  • MRI引导的纤维化消融联合PVI与单纯PVI相比,房性心律失常复发率无显著差异。
  • 纤维化消融组安全终点事件发生率更高(2.2% vs 0,P=0.001),包括6例缺血性卒中。
  • 研究结果不支持使用MRI引导的纤维化消融治疗持续性房颤。

核心结论

  • 在持续性房颤患者中,MRI引导的纤维化消融联合PVI与单纯PVI导管消融相比,房性心律失常复发无显著差异。
  • 研究结果不支持使用MRI引导的纤维化消融治疗持续性房颤。

研究设计与样本

  • 研究者发起的多中心随机临床试验,纳入10个国家44个学术和非学术中心。
  • 2016年7月至2020年1月入组843例有症状或无症状的持续性房颤接受消融患者,随访至2021年2月19日。
  • 患者随机分配至PVI联合MRI引导的房性纤维化消融组(421例)或单纯PVI组(422例)。

主要发现

  • 共843例随机(平均年龄62.7岁;女性178例[21.1%]),815例(96.9%)完成90天空白期并纳入疗效分析。
  • 纤维化消融联合PVI组房性心律失常复发175例(43.0%),单纯PVI组188例(46.1%),无显著差异(HR 0.95,95%CI 0.77-1.17,P=0.63)。
  • 纤维化消融联合PVI组安全终点事件发生率更高(9例[2.2%] vs 单纯PVI组0例;P=0.001)。
  • 纤维化消融联合PVI组6例(1.5%)发生缺血性卒中,单纯PVI组无。
  • 纤维化消融联合PVI组发生2例死亡,其中第一例可能与手术相关。

关键数值与推荐

  • 主要终点为消融后90天空白期后首次房性心律失常复发时间。
  • 主要安全复合终点定义为消融后30天内发生以下事件之一或以上:卒中、肺静脉狭窄、出血、心力衰竭或死亡。

临床怎么用

  • 研究结果不支持使用MRI引导的纤维化消融治疗持续性房颤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ablation of persistent atrial fibrillation (AF) remains a challenge. Left atrial fibrosis plays an important role in the pathophysiology of AF and has been associated with poor procedural outcomes. OBJECTIVE: To investigate the efficacy and adverse events of targeting atrial fibrosis detected on magnetic resonance imaging (MRI) in reducing atrial arrhythmia recurrence in persistent AF. DESIGN, SETTING, AND PARTICIPANTS: The Efficacy of Delayed Enhancement-MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation trial was an investigator-initiated, multicenter, randomized clinical trial involving 44 academic and nonacademic centers in 10 countries. A total of 843 patients with symptomatic or asymptomatic persistent AF and undergoing AF ablation were enrolled from July 2016 to January 2020, with follow-up through February 19, 2021. INTERVENTIONS: Patients with persistent AF were randomly assigned to pulmonary vein isolation (PVI) plus MRI-guided atrial fibrosis ablation (421 patients) or PVI alone (422 patients). Delayed-enhancement MRI was performed in both groups before the ablation procedure to assess baseline atrial fibrosis and at 3 months postablation to assess for ablation scar. MAIN OUTCOMES AND MEASURES: The primary end point was time to first atrial arrhythmia recurrence after a 90-day blanking period postablation. The primary safety composite outcome was defined by the occurrence of 1 or more of the following events within 30 days postablation: stroke, PV stenosis, bleeding, heart failure, or death. RESULTS: Among 843 patients who were randomized (mean age 62.7 years; 178 [21.1%] women), 815 (96.9%) completed the 90-day blanking period and contributed to the efficacy analyses. There was no significant difference in atrial arrhythmia recurrence between groups (fibrosis-guided ablation plus PVI patients, 175 [43.0%] vs PVI-only patients, 188 [46.1%]; hazard ratio [HR], 0.95 [95% CI, 0.77-1.17]; P = .63). Patients in the fibrosis-guided ablation plus PVI group experienced a higher rate of safety outcomes (9 [2.2%] vs 0 in PVI group; P = .001). Six patients (1.5%) in the fibrosis-guided ablation plus PVI group had an ischemic stroke compared with none in PVI-only group. Two deaths occurred in the fibrosis-guided ablation plus PVI group, and the first one was possibly related to the procedure. CONCLUSIONS AND RELEVANCE: Among patients with persistent AF, MRI-guided fibrosis ablation plus PVI, compared with PVI catheter ablation only, resulted in no significant difference in atrial arrhythmia recurrence. Findings do not support the use of MRI-guided fibrosis ablation for the treatment of persistent AF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02529319.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Marrouche NF, Wazni O, McGann C, et al. Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. JAMA. 2022. PMID: 35727277. doi:10.1001/jama.2022.8831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。